Interpreting Respiratory Safety in an Oliceridine Gastroscopy Trial [Letter]
Drug Design, Development and Therapy · 2026-08 · Volume 20 · 1-2
DOI: 10.2147/dddt.s644900 ↗Kurz gefasst
Leserbrief in der Zeitschrift Drug Design, Development and Therapy, 2026-08. Verfasst von Ang Liu. Beteiligte Einrichtung: Heze Hospital Affiliated to Shandong First Medical University, Heze Municipal Hospital, Heze, Shandong, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
We read with great interest the randomized trial by Hu et al, which compared three doses of oliceridine with sufentanil, each combined with propofol, for painless gastroscopy. 1 The authors reported substantially less respiratory depression with oliceridine 10 or 20 μg/kg than with oliceridine 30 μg/kg or sufentanil 0.1 μg/kg and identified 20 μg/kg as providing the most favorable balance between sedation success and respiratory safety.This clinically relevant dose-finding comparison is promising.Nevertheless, three issues should be clarified before the respiratory safety conclusion is accepted.First, the prospectively registered outcomes and design differ materially from the published report.The Chinese Clinical Trial Registry entry (ChiCTR2500097246) identifies mean arterial pressure, heart rate, and SpO 2 as primary outcomes; it does not designate the composite incidence of respiratory depression as the primary outcome.The registry also specifies 120 participants (30 per group), recruitment from March to April 2025, ASA physical status I-II, and a study end date of September 30, 2025.In contrast, the article reports a pilot-based sample size of 188, recruitment from July to October 2025, inclusion of ASA I-III, and respiratory depression as the primary outcome.The registry still indicates "not yet recruiting" and provides no measurement time points or methods for the registered outcomes.Furthermore, the registry states that individual participant data would be made publicly available with publication, whereas the article provides no repository or dataset.These changes may represent legitimate protocol amendments, but their timing and rationale are essential.CONSORT 2025 recommends identifying the trial protocol and statistical analysis plan and describing important changes made after trial commencement with reasons. 2 We therefore invite the authors to provide the dated protocol, statistical analysis plan, ethics approval for any amendments, and confirmation that the revised primary outcome and sample size were established before examination of trial data.Second, the analysis did not preserve all randomized participants.One participant in the 20 μg/kg group experienced SpO 2 15 seconds, or SpO 2
Autor:innen und Institutionen
- Heze Hospital Affiliated to Shandong First Medical University, Heze Municipal Hospital, Heze, Shandong, People's Republic of China.
Zitieren
APA
Liu, A. (2026). Interpreting Respiratory Safety in an Oliceridine Gastroscopy Trial [Letter]. Drug Design, Development and Therapy, Volume 20, 1-2. https://doi.org/10.2147/dddt.s644900
Vancouver
Liu A. Interpreting Respiratory Safety in an Oliceridine Gastroscopy Trial [Letter]. Drug Design, Development and Therapy. 2026;Volume 20:1-2. doi:10.2147/dddt.s644900
BibTeX
@article{Liu2026,
author = {Liu, Ang},
title = {Interpreting Respiratory Safety in an Oliceridine Gastroscopy Trial [Letter]},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--2},
doi = {10.2147/dddt.s644900}
}
EUVIMED